Canada markets close in 4 hours 57 minutes
  • S&P/TSX

    20,297.28
    -274.02 (-1.33%)
     
  • S&P 500

    4,326.46
    -83.67 (-1.90%)
     
  • DOW

    33,948.91
    -415.59 (-1.21%)
     
  • CAD/USD

    0.7915
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    84.58
    +1.27 (+1.52%)
     
  • BTC-CAD

    46,225.59
    +2,786.11 (+6.41%)
     
  • CMC Crypto 200

    831.19
    +10.60 (+1.29%)
     
  • GOLD FUTURES

    1,845.90
    +4.20 (+0.23%)
     
  • RUSSELL 2000

    1,992.92
    -40.59 (-2.00%)
     
  • 10-Yr Bond

    1.7580
    +0.0230 (+1.33%)
     
  • NASDAQ

    13,511.91
    -343.22 (-2.48%)
     
  • VOLATILITY

    32.78
    +2.88 (+9.63%)
     
  • FTSE

    7,377.02
    +79.87 (+1.09%)
     
  • NIKKEI 225

    27,131.34
    -457.03 (-1.66%)
     
  • CAD/EUR

    0.7017
    +0.0034 (+0.49%)
     

UPDATE 1-U.S. FDA declines to approve United-Mannkind's lung disease therapy

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • MNKD
  • UTHR

(Adds background, Mannkind shares)

Oct 18 (Reuters) - The U.S. Food and Drug Administration has declined to approve a lung disease therapy developed by United Therapeutics and Mannkind Corp, citing an inspection issue at a third-party facility.

United said on Monday the health regulator's draft label for the drug, Tyvaso DPI, includes its use as a treatment for pulmonary arterial hypertension (PAH), as well as PAH associated with interstitial lung disease (PH-ILD).

In its complete response letter, the agency did not cite any deficiencies related to operations at MannKind's device manufacturing and testing facility for Tyvaso DPI.

Shares of Mannkind were down 17.9% at $4.18 in premarket trading.

While PAH is a type of high blood pressure that affects blood vessels in the lungs, PH-ILDs are a group of diseases that cause inflammation and scarring of the lung tissue, making it harder to breathe. (Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Ramakrishnan M.)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting